Search

Glatiramer

[A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune … [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017.

Gepefrine

Perflubron

Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

PI-166

It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents. … PI-166 is a small organic compound with specific avidity to liver cancer cells.

IDD-1

Lipids promote the fusion of liposomes to cells. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

Inhibitor of P38 Kinase

This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. … This drug is known to target mitogen-activated protein kinase 14.

Quinine

Quinine (GLS-1200) was also investigated in clinical trials for its efficacy in preventing SARS-CoV-2 infection (NCT04408183, terminated) and is planned to be evaluated for preventing sinusitis after endoscopic

Cysteamine

Marketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.[L15601]

PPI-1019

Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

Narsoplimab

[A241030] Evidence increasingly points to a role for the complement system in TMA.